Short-term Efficacy and Safety of Lurasidone Versus Placebo in Antipsychotic-Naïve vs. Previously Treated Adolescents with an Acute Exacerbation of Schizophrenia.

Correll, Christoph U; Tocco, Michael; Hsu, Jay; Goldman, Robert; Pikalov, Andrei

Correll, Christoph U; Tocco, Michael; Hsu, Jay; Goldman, Robert; Pikalov, Andrei.

Afiliação

Correll CU; Department of Psychiatry, Northwell Health, The Zucker Hillside Hospital, Glen Oaks, NY, USA.
Tocco M; Hofstra Northwell School of Medicine, Department of Psychiatry and Molecular Medicine, Hempstead, NY, USA.
Hsu J; Charité Universitätsmedizin, Department of Child and Adolescent Psychiatry, Berlin, Germany.
Goldman R; Sunovion Pharmaceuticals Inc, Fort Lee, NJ, and Marlborough, MA.
Pikalov A; Sunovion Pharmaceuticals Inc, Fort Lee, NJ, and Marlborough, MA.

Eur Psychiatry ; : 1-35, 2022 Mar 24.

Article em En | MEDLINE | ID: mdl-35322769

Palavras-chave

atypical antipsychotic; controlled clinical trial; lurasidone; schizophrenia; second generation antipsychotic

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: Eur Psychiatry Assunto da revista: PSIQUIATRIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Reino Unido

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google